# Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib

> **NCT01933945** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1676 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **PROCEDURE:** TACE (transarterial chemoembolization)
- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT01933945
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-28
- **Primary completion:** 2017-07-22
- **Final completion:** 2017-11-10
- **Target enrollment:** 1676 (ACTUAL)
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01933945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01933945, "Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01933945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*